Genetic Polymorphisms Might Predict Suicide Attempts in Mental Disorder Patients: A Systematic Review And Meta-Analysis

Abstract

The aim of the present study was to analyze if the genetic polymorphisms might predict suicide attempts in mental disorder patients. The literature review and meta-analysis were conducted using the PubMed/Medline, Web of science and Scopus database using the terms: "5-HTT or SLC6A4 or 5-SERT and suicide, suicidal ideation or suicidal behavior or suicidal attempt". Thirty articles were analyzed. We found 17 articles that showed association and 13 articles that showed no association between LPR serotonin transporter polymorphism and suicide. A higher study of suicide identified the serotonin transporter polymorphism in patients with schizophrenia, mental disorder, major depression and bipolar disorder. There is an association between the serotonin-transporter-linked polymorphic region and suicidal behavior. The mental disorders with greater relationship with the suicide were the bipolar disorder, major depression and schizophrenia. The L allele had higher risk for suicide.

Predictors for self‐directed aggression in Italian prisoners include externalizing behaviors, childhood trauma and the serotonin transporter gene polymorphism 5‐HTTLPR

“…, or the high activity variant (de Medeiros Alves et al, 2015, (Hung et al , 2011, Shinozaki et al , 2013) that is associated with increased risk for suicidal behavior. Another recent meta-analysis has shown a significant association, between the 5-HTTLPR low activity variant and violent suicidal behavior at least in Caucasians but indicates that the high activity variant could confer risk in Asian populations (Antypa et al , 2013).…”

“…As discussed earlier, results of numerous studies are conflicting as to whether it is the low activity 5-HTTLPR variant (Caspi et al 2003;Gibb et al 2006;Roy et al 2007;Zalsman et al 2006), or the high activity variant (Hung et al 2011;de Medeiros Alves et al 2015;Shinozaki et al 2013) that is associated with increased risk for suicidal behavior. Another recent meta-analysis has shown a significant association, between the 5-HTTLPR low activity variant and violent suicidal behavior at least in Caucasians but indicates that the high activity variant could confer risk in Asian populations (Antypa et al 2013).…”

“…Furthermore, a study in Caucasian depressed inpatients indicated that the LL genotype increased risk for suicidal behavior (Shinozaki et al , 2013). A recent meta-analysis showed that the L allele was associated with increased risk for suicidal behavior in patients with psychiatric disorders (De Medeiros Alves et al , 2015). At this point there are no published studies about main effects of 5-HTTLPR risk for self-mutilatory behavior.…”

“…The serotonin transporter (5-HTT) plays a key role in regulating neuronal 5-HT by controlling 5-HT reuptake from the synaptic cleft. Two meta-analyses have shown that 5-HTTLPR, a functional promoter polymorphism in SLC6A4, the gene encoding the 5-HTT, is associated with suicidal behavior in a number of populations, such as Caucasian, African American, Han Chinese and Hispanic (Clayden et al 2012;de Medeiros Alves et al 2015). This common Variable Number Tandem Repeat (VNTR) polymorphism (44-basepair insertion/deletion) alters transcription such that short 'S' allele is associated with an approximately 50% reduction in 5-HTT availability and concomitant increase in synaptic 5-HT and reduced neuronal 5-HT uptake (Heils et al 1996).…”

Long noncoding RNA expression in peripheral blood mononuclear cells and suicide risk in Chinese patients with major depressive disorder

“…One strategy proposed by the National Action Alliance for Suicide Prevention to predict suicide is requiring the identification of reliable biomarkers capable of identifying those at current or future risk (NAAfSPRPT ). Peripheral biomarkers for suicide have been performed, such as genetic polymorphisms of 5‐HT (de Medeiros Alves, Bezerra, de Andrade, de Melo Neto, & Nardi, ; Pandey & Dwivedi, ), NE function and its metabolite 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) (Sher et al., ; Tripodianakis, Markianos, Sarantidis, & Agouridaki, ), abnormal HPA axis (Yerevanian, Feusner, Koek, & Mintz, ), and low plasma BDNF (Deveci, Aydemir, Taskin, Taneli, & Esen‐Danaci, ; Pandey et al., ).…”